ImmunoGen Reports Recent Progress and 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Immunogen (IMGN) Gains 25% Following Results
February 14, 2020 11:37 AM ESTImmunogen (NASDAQ: IMGN) surges 25% on strong results and outlook
... MoreImmunogen (IMGN) Tops Q4 EPS by 8c; Guides Higher
February 14, 2020 6:35 AM ESTImmunogen (NASDAQ: IMGN) reported Q4 EPS of $0.03, $0.08 better than the analyst estimate of ($0.05). Revenue for the quarter came in at $44.9 million versus the consensus estimate of $29.33 million.
Following the results of FORWARD I, we moved decisively to restructure the business to reduce our costs, prioritized our portfolio to focus on our most promising programs, and worked constructively with FDA to define an accelerated path to approval for mirvetuximab, said Mark Enyedy, ImmunoGens... More
